Latest News on CERT

Financial News Based On Company


Advertisement
Advertisement

Avoiding Lag: Real-Time Signals in (CERT) Movement

https://news.stocktradersdaily.com/news_release/15/Avoiding_Lag:_Real-Time_Signals_in_CERT_Movement_111526040001_1794733201.html
This article analyzes Certara Inc. (NASDAQ: CERT) using AI models to generate distinct trading strategies for various risk profiles. It identifies conflicting sentiment across horizons, suggesting choppy conditions, and provides specific entry, target, and stop loss levels for position, momentum breakout, and risk hedging strategies. The analysis highlights that no resistance levels remain above the current price, indicating compelling upside potential.

What Certara (CERT) Narrowed Guidance Means For Shareholders

https://simplywall.st/stocks/us/healthcare/nasdaq-cert/certara/news/what-certara-cert-narrowed-guidance-means-for-shareholders
Certara reported mixed third-quarter 2026 results, showing profitability for the quarter but a net loss over the first nine months, leading management to narrow its full-year revenue growth guidance to 2% to 3%. This tighter outlook intensifies focus on Certara's ability to convert regulatory advancements and product momentum into consistent earnings and manage high operating costs. The investment narrative now centers on whether new AI-enabled platforms and regulatory wins can drive more predictable revenue growth to justify current spending and analyst projections for future earnings.

Can Certara (CERT) Justify Its Valuation On Stronger Q3 Results And Tighter 2026 Guidance?

https://simplywall.st/stocks/us/healthcare/nasdaq-cert/certara/news/can-certara-cert-justify-its-valuation-on-stronger-q3-result
Certara (CERT) recently reported stronger Q3 2026 results with increased sales and net income, along with a tighter full-year revenue growth guidance of 2% to 3%. Despite a recent 27.14% 30-day share price return, Simply Wall St's analysis suggests the stock is currently 7% overvalued at $11.90, compared to a fair value of $11.08. Bulls highlight earnings rebound and new AI-enabled platforms, while bears point to multi-year losses and long-term share price performance.

Certara (CERT) Q3 2026 Earnings Call: Software Growth Reaches 11%

https://www.tradingkey.com/news/transcripts/262293783-
Certara (CERT) reported a 4% year-over-year revenue increase to $94.9 million in Q3 2026, driven by an 11% rise in software revenue, marking its first double-digit organic software growth in two years. Adjusted EBITDA grew 6% to $30.2 million, with margins improving to 31.8%. While software bookings and cloud conversions show strong momentum, services revenue declined 2%, and management narrowed full-year 2026 revenue growth guidance to 2%-3% while updating adjusted diluted EPS to $0.31-$0.34.

Jefferies raises Certara stock price target to $12 on software growth

https://www.investing.com/news/analyst-ratings/jefferies-raises-certara-stock-price-target-to-12-on-software-growth-93CH-5008707
Jefferies has increased its price target for Certara Inc. (NASDAQ:CERT) to $12.00 from $7.45, maintaining a Hold rating due to improving software growth, with organic bookings accelerating. The stock has surged 95% in six months and currently trades slightly above the new target, while UBS also raised its price target to $13.00, citing strong demand and product portfolio momentum. Despite the upward revisions, Jefferies notes that there is still "work to do" to reach management's long-term double-digit growth objectives.
Advertisement

UBS raises Certara stock price target on software demand strength

https://www.investing.com/news/analyst-ratings/ubs-raises-certara-stock-price-target-on-software-demand-strength-93CH-5006678
UBS has increased its price target for Certara Inc. (NASDAQ:CERT) from $10.00 to $13.00, while maintaining a Neutral rating. This adjustment reflects improved demand in the biopharma sector and strong performance in Certara's software portfolio, evidenced by a 15% year-over-year rise in software bookings and 11% growth in software revenue. Despite a decline in services bookings and revenue, UBS raised its revenue and EBITDA estimates for fiscal years 2027 and 2028, noting the potential for a software re-acceleration.

Key facts: Certara Bookings Up 4%; Losses Widen; Phoenix Cloud 10%

https://www.tradingview.com/news/tradingview:89fc2b3e389e2:0-key-facts-certara-bookings-up-4-losses-widen-phoenix-cloud-10/
Certara (CERT) reported a 4% increase in third-quarter bookings to $92.5 million, with software bookings up 15%. The company experienced wider losses from continuing operations due to higher operating costs but saw nearly 10% of Phoenix accounts migrate to its cloud offering ahead of schedule. Certara plans to accelerate these cloud conversions in 2027, despite potential near-term revenue impact.

Certara stock hits 52-week high at $12.0 despite annual decline

https://www.investing.com/news/company-news/certara-stock-hits-52week-high-at-120-despite-annual-decline-93CH-5004766
Certara Inc. (CERT) stock reached a 52-week high of $11.73, currently trading at $11.56, marking a significant 160% surge from its 52-week low. Despite this recent momentum, including a 79% return over six months and a 26% year-to-date gain, the stock has seen an annual decline of 4.15%. UBS has resumed coverage with a Neutral rating and a $10 price target, noting the stock is inexpensive compared to its history but fairly valued against peers, with limited visible catalysts for earnings growth.

Certara Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62923847/certara-q3-2026-earnings-call-transcript
Certara reported a 4% year-over-year revenue increase in Q3 2026, reaching $94.9 million, primarily driven by 11% growth in software revenue. The company also saw a 6% increase in adjusted EBITDA to $30.2 million, attributed to operational efficiencies. Certara is focusing on integrating AI, expanding cloud capabilities, and targeting growth in biotech, mid-sized pharma, and the APAC region, while narrowing its full-year revenue growth guidance to 2-3%.

Certara, Inc. (CERT) Reports In-Line Q3 EPS

https://www.streetinsider.com/Earnings/Certara%2C+Inc.+%28CERT%29+Reports+In-Line+Q3+EPS/27294563.html
Certara, Inc. (NASDAQ: CERT) announced its Q3 earnings, reporting an EPS of $0.09, which met analyst expectations. The company also reported revenue of $94.9 million, exceeding the consensus estimate of $92.31 million.
Advertisement

Certara, Inc. (CERT) Seasonal returns chart

https://uk.finance.yahoo.com/quote/CERT/seasonality/
This article provides a seasonal returns chart for Certara, Inc. (CERT), showing the average monthly price return between 2020 and 2026. As of November 2, the stock was trading at $10.71, down 2.81% at market close.

Earnings Preview: Certara to Report Financial Results Pre-market on November 05

https://www.moomoo.com/news/post/1003074063/earnings-preview-certara-to-report-financial-results-pre-market-on
Certara is scheduled to report its financial results pre-market on November 05. The company is expected to announce earnings per share (EPS) of $0.06 for the quarter, with revenue projected to be around $93.02 million. Analysts have provided varying ratings, with a consensus "Buy" rating and a target price range from $12 to $22.

Certara, Inc. (CERT) Seasonal returns chart

https://au.finance.yahoo.com/quote/CERT/seasonality/
This article provides a seasonal returns chart for Certara, Inc. (CERT), showing the average monthly price return between 2020 and 2026. The stock's current real-time price on NasdaqGS is 10.71 USD, with a recent decline of 2.81%.

Certara, Inc. (CERT) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/CERT/seasonality/
The Yahoo Finance page for Certara, Inc. (CERT) displays an "Oops, something went wrong" message, indicating an error in loading content. Despite the error, some stock information is visible, showing CERT at 11.02, down 1.61% at market close on October 30, and then up 0.54% after hours. The page also includes navigation elements and placeholders for historical seasonality data.

Certara, Inc. (CERT) Stock forecasts

https://sg.finance.yahoo.com/research/reports/ARGUS_6346_QuantitativeReport_1793145600000/
Argus has raised its target price for Certara Inc. (CERT) to $9.00. The company, which trades under the symbol CERT in the Healthcare sector, is currently priced at $11.02. Certara Inc. utilizes biosimulation software and technology to expedite drug discovery and development processes.
Advertisement

Certara's 73% Rally Meets Its Real Test: Can Services Finally Turn As Software Rebounds?

https://finviz.com/news/410343/certaras-73-rally-meets-its-real-test-can-services-finally-turn-as-software-rebounds
Certara (CERT) shares have rallied 73% despite modest revenue and profit growth forecasts, driven by expectations of a turnaround in software momentum and new leadership. The upcoming third-quarter report is crucial to demonstrate whether this story is moving from promise to proof, particularly concerning the performance of its services segment and improved margins. The market is looking for solid bookings growth in software and signs that the recent commercial restructuring in services is effectively converting its pipeline.

Why Are AngloGold Ashanti (NYSE:AU), Ramaco Resources (NASDAQ:METC), SailPoint (NASDAQ:SAIL) and Certara (NASDAQ:CERT) Rising In early trading indications?

https://kalkine.ca/news/general-news/why-are-anglogold-ashanti-nyseau-ramaco-resources-nasdaqmetc-sailpoint-nasdaqsail-and-certara-nasdaqcert-rising-in-early-trading-indications
This article examines the individual drivers behind the early trading gains of AngloGold Ashanti (NYSE:AU), Ramaco Resources (NASDAQ:METC), SailPoint (NASDAQ:SAIL), and Certara (NASDAQ:CERT). While no immediate news from October 23-26, 2026, was found for any of the four, their respective price movements are linked to recent financial reports and operational updates. The article suggests that the broad market movement may be contributing to the synchronized early trading gains across these diverse companies.

Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026

https://www.manilatimes.net/2026/10/26/tmt-newswire/globenewswire/certara-to-report-third-quarter-2026-financial-results-on-november-5th-2026/2453937/amp
Certara, Inc. (Nasdaq: CERT) announced that it will release its third-quarter 2026 financial results before market open on Thursday, November 5th, 2026. Following the release, company management will host a conference call at 8:30 AM ET to discuss the financial outcomes. Investors can access the live webcast or a replay through the Certara Investor Relations website.

Certara, Inc. Estimates – NASDAQ:CERT

https://www.tradingview.com/symbols/NASDAQ-CERT/financials-estimates/
This article from TradingView provides an overview of Certara, Inc. (NASDAQ: CERT) financial data and analyst estimates. It highlights various financial statements like income, balance sheet, and cash flow, allowing users to compare actual results with average, high, and low estimates and visualize trends over time. The content explicitly states it is not investment advice and encourages users to conduct their own research.

Certara, Inc. (CERT) options chain

https://uk.finance.yahoo.com/quote/CERT/options/?date=1795132800&straddle=false&type=all
This article from Yahoo Finance provides the options chain for Certara, Inc. (CERT). It displays real-time price data, with the stock trading at $9.79, up 3.54% at market close on October 20th. The options data, delayed by 15 minutes, shows no available calls or puts.
Advertisement

Certara reports on November 5: USD 0.06 guides Certara stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/certara-reports-on-november-5-usd-0-06-guides-certara-stock/70377589
Certara is set to report its third-quarter 2026 results on November 5, 2026, with an expected adjusted earnings per share of USD 0.06. The company's second-quarter revenue of USD 93.27 million fell short of the USD 98.09 million consensus estimate. Certara stock was trading at EUR 8.62 on October 20, 2026, in Germany, and USD 9.66 on Nasdaq, with a market capitalization of USD 1.5 billion.

KeyBanc Maintains Certara(CERT.US) With Buy Rating, Raises Target Price to $12

https://www.moomoo.com/news/post/1001447180/keybanc-maintains-certara-certus-with-buy-rating-raises-target-price
KeyBanc has reiterated its Buy rating for Certara (CERT.US) and increased the target price to $12. This indicates a positive outlook from the analyst firm regarding Certara's stock performance.

InvestingPro Fair Value analysis captures 67% gain on Certara stock By Investing.com

https://www.investing.com/news/investment-ideas/investingpro-fair-value-analysis-captures-67-gain-on-certara-stock-93CH-4955395
InvestingPro's Fair Value analysis accurately predicted a significant gain for Certara (NASDAQ:CERT) stock, which surged 66.61% to $9.37 after being identified as undervalued at $5.48 in April 2026. The analysis successfully looked beyond short-term challenges to recognize Certara's intrinsic worth, strategic strengths like a new CEO, strong market position, and an Nvidia partnership. This case demonstrates how comprehensive Fair Value methodology, integrating multiple valuation approaches, can identify mispriced opportunities and provide actionable insights for investors.

InvestingPro Fair Value analysis captures 67% gain on Certara stock By Investing.com

https://za.investing.com/news/stock-market-news/investingpro-fair-value-analysis-captures-67-gain-on-certara-stock-93CH-4509859
InvestingPro's Fair Value analysis successfully identified Certara (NASDAQ:CERT) as an undervalued stock in early April 2026, leading to a 66.61% gain for investors. Despite initial challenges and missed earnings forecasts, the analysis looked beyond short-term noise to pinpoint the company's intrinsic worth, driven by strong fundamentals and strategic innovations like its partnership with Nvidia. This case highlights how comprehensive valuation methodologies can uncover significant investment opportunities.

InvestingPro Fair Value analysis captures 67% gain on Certara stock By Investing.com

https://ca.investing.com/news/stock-market-news/investingpro-fair-value-analysis-captures-67-gain-on-certara-stock-93CH-4886425
InvestingPro's Fair Value analysis successfully identified Certara (NASDAQ:CERT) as a significant investment opportunity in April 2026 when it was trading at $5.48. The stock subsequently surged by 66.61% to $9.37, exceeding the initial 51.46% upside estimate. This case demonstrates the efficacy of intrinsic value analysis in uncovering mispriced opportunities, even amidst negative short-term news, and highlights Certara's strategic moves, such as its partnership with Nvidia, as key drivers for its growth.
Advertisement

TD Cowen lifts target to USD 11.00 for Certara stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/td-cowen-lifts-target-to-usd-11-00-for-certara-stock/70333613
TD Cowen has raised its price target for Certara (CERT) stock to USD 11.00 from USD 9.00, citing the company's recent performance. This adjustment comes after Certara reported second-quarter revenue of USD 93.27 million, which was below the expected USD 98.09 million, and recorded a net loss of USD 55.27 million. The stock was trading at EUR 8.61 on October 15, 2026, and is scheduled to report earnings again on November 5, 2026.

CERT Maintained by TD Cowen -- Price Target Raised to $11.00

https://www.gurufocus.com/news/9121432/cert-maintained-by-td-cowen-price-target-raised-to-1100?utm_source=marketwatch&utm_medium=syndication&utm_campaign=headlines&r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news
TD Cowen maintained a 'Buy' rating for Certara (CERT) and raised its price target from $9.00 to $11.00, reflecting optimism about the company's growth potential. GuruFocus assesses Certara as 20.4% undervalued with a GF Value™ of $12.18, despite being unprofitable, and notes a GF Score™ of 73/100 indicating solid overall performance. Guru activity shows a positive sentiment, with 7 gurus holding positions and no insider selling in the last three months.

CERT Maintained by TD Cowen -- Price Target Raised to $11.00

https://www.gurufocus.com/news/9121432/cert-maintained-by-td-cowen--price-target-raised-to-1100
TD Cowen has reiterated a 'Buy' rating for Certara (CERT) and increased its price target from $9.00 to $11.00, signaling optimism about the company's future. GuruFocus assesses Certara as undervalued with a GF Value™ of $12.18 against a current price of $9.70, despite its current unprofitability. The company's GF Score™ of 73/100 reflects strong valuation and momentum, although financial strength and profitability show room for improvement.

Certara Stock Gains Fresh Analyst Backing for AI Turnaround

https://simplywall.st/stocks/us/healthcare/nasdaq-cert/certara/news/certara-stock-gains-fresh-analyst-backing-for-ai-turnaround/amp
Certara has received renewed analyst attention focusing on its early-stage turnaround, particularly its use of AI in biosimulation and model-informed drug development. Analysts are closely watching if Certara's significant AI investments will translate into higher bookings and predictable subscription revenue, especially as the company is currently unprofitable. The investment narrative hinges on successful execution by management to convert its AI and biosimulation pipeline into profitable customer adoption.

Certara Inc. Research & Ratings | CERT

https://www.barrons.com/market-data/stocks/cert/research-ratings?countrycode=mx&mod=quotes
This article provides research and ratings for Certara Inc. (CERT), including analyst ratings, price targets, and earnings estimates. It details the company's financial metrics, past quarterly actuals, and future earnings projections, alongside disclaimers about the data sources.
Advertisement

Certara Inc. Advanced Charts | CERT

https://www.barrons.com/market-data/stocks/cert/interactive-chart?countrycode=mx
This article provides advanced charting and market data for Certara Inc. (CERT), including analyst ratings, key financial metrics, and price performance. It details the average price target from analysts, various stock statistics, and data provider information, clarifying the sources and limitations of the financial data presented.

Certara, Inc. (CERT) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_6346_QuantitativeReport_1791331200000
This article provides a stock forecast for Certara Inc. (CERT), highlighting its use of biosimulation software for drug discovery. An Argus report from October 7, 2026, offers insights and a current price of $9.13, encouraging users to upgrade for full access to premium research.

Certara Price Target Raised to $9.00/Share From $7.50 by Barclays

https://www.moomoo.com/news/post/1000696987/certara-price-target-raised-to-9-00-share-from-7
Barclays has increased its price target for Certara to $9.00 per share, up from the previous $7.50. This adjustment indicates a more optimistic outlook from Barclays regarding the company's future stock performance.

Barclays raises target for Certara stock from USD 7.50 to USD 9.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/barclays-raises-target-for-certara-stock-from-usd-7-50-to-usd-9-00/70268417
Barclays has increased its price target for Certara (CERT) stock from USD 7.50 to USD 9.00, maintaining an Equal Weight rating. This adjustment comes despite Certara reporting second-quarter revenue of USD 93.27 million, which fell short of the USD 98.09 million expectation. The stock experienced a 4.69 percent drop in after-hours trading, settling at EUR 7.73.

Certara Is Maintained at Equal-Weight by Barclays

https://www.moomoo.com/news/post/1000696985/certara-is-maintained-at-equal-weight-by-barclays
Barclays has reiterated its "Equal-Weight" rating on Certara. The article states this change.
Advertisement

How Certara Inc. (CERT) Affects Rotational Strategy Timing

https://news.stocktradersdaily.com/news_release/89/How_Certara_Inc._CERT_Affects_Rotational_Strategy_Timing_100526020601_1791223561.html
Certara Inc. (NASDAQ: CERT) shows strong near and mid-term sentiment, with a breakout underway and compelling upside potential due to no resistance levels above the current price. However, its long-term outlook is weak. The article provides institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.

How Certara Inc. (CERT) Affects Rotational Strategy Timing

https://news.stocktradersdaily.com/news_release/1/How_Certara_Inc._CERT_Affects_Rotational_Strategy_Timing_100526020601_1791223561.html
Certara Inc. (CERT) is exhibiting strong near and mid-term sentiment, with a breakout underway and no resistance levels above the current price, indicating compelling upside potential. However, its long-term outlook appears weak. The article details AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide potential trading decisions for different risk profiles.

UBS Initiates Certara(CERT.US) With Hold Rating, Announces Target Price $10

https://www.moomoo.com/news/post/1000453349/ubs-initiates-certara-certus-with-hold-rating-announces-target-price
UBS has initiated coverage on Certara (CERT.US) with a Hold rating. The firm has set a price target of $10 for the company's stock.

Certara Cut to Neutral From Buy by UBS

https://www.moomoo.com/news/post/1000474096/certara-cut-to-neutral-from-buy-by-ubs
UBS has downgraded Certara (NASDAQ: CERT) from a "Buy" rating to a "Neutral" rating. This change in analyst sentiment indicates a revised outlook on the company's stock performance.

Certara Launches Marvin Cloud Worldwide, Bringing Professional Chemical Structure Drawing to Independent Scientists and Students

https://biobuzz.io/news/certara-launches-marvin-cloud-worldwide-bringing-professional-chemical-structure-drawing-to-independent-scientists-and-students/
Certara, Inc. announced the worldwide availability of Marvin Cloud, a browser-based, cloud-hosted chemical sketching platform developed by its subsidiary, Chemaxon. This platform aims to provide independent scientists, students, and academics with access to professional-grade chemical structure drawing tools without requiring institutional deployment. Marvin Cloud offers core Marvin capabilities through individual subscriptions with flexible pricing, continuing Chemaxon's tradition of supporting scientific breakthroughs in chemistry.
Advertisement

CERT Downgraded by UBS -- Rating Changed to Neutral

https://www.gurufocus.com/news/9103879/cert-downgraded-by-ubs-rating-changed-to-neutral
UBS has downgraded Certara (CERT) to a Neutral rating, maintaining a price target of $10.00. Despite the downgrade, GuruFocus assesses CERT as 24.5% undervalued with a GF Value™ of $12.23 and a solid GF Score™ of 74. Seven gurus hold CERT, with five adding to their positions, indicating continued investor interest despite the cautious analyst outlook.

UBS Downgrades Certara to Neutral From Buy, $10 Price Target

https://www.moomoo.com/news/post/1000464064/ubs-downgrades-certara-to-neutral-from-buy-10-price-target
UBS has downgraded Certara (NASDAQ: CERT) to Neutral from Buy, setting a new price target of $10. This adjustment reflects a revised outlook on the company's stock performance.

UBS resumes Certara stock coverage with neutral rating, $10 target By Investing.com

https://ng.investing.com/news/stock-market-news/ubs-resumes-certara-stock-coverage-with-neutral-rating-10-target-93CH-2715658
UBS has resumed coverage of Certara Inc. (NASDAQ:CERT) with a Neutral rating and a $10.00 price target, noting the stock is inexpensive historically but fairly valued against peers. Despite the stock appearing undervalued according to InvestingPro data, UBS highlights limited near-term catalysts and visibility into software growth and margin expansion. The firm also pointed out that Certara's cost savings initiatives are being offset by R&D investments, hindering margin improvement.

UBS resumes Certara stock coverage with neutral rating, $10 target By Investing.com

https://in.investing.com/news/stock-market-news/ubs-resumes-certara-stock-coverage-with-neutral-rating-10-target-93CH-5612554
UBS has resumed coverage of Certara Inc. (NASDAQ:CERT) with a Neutral rating and a $10.00 price target, noting the stock is inexpensive historically but fairly valued against peers. While InvestingPro data suggests it's undervalued, UBS points to a muted near-term catalyst path and limited visibility into software growth and margin expansion as challenges. Certara recently missed Q2 2026 financial expectations, with adjusted earnings of $0.08 per share on revenue of $93.3 million, falling short of analyst projections.

Certara, Inc. (CERT) Stock forecasts

https://sg.finance.yahoo.com/research/reports/ARGUS_6346_QuantitativeReport_1790121600000/
This article provides stock forecasts for Certara, Inc. (CERT) and includes general market data for various global indices and cryptocurrencies. It appears to be a stub or an article with missing content, as it primarily displays navigation and market data without specific analysis for Certara. The page also shows an error message for data retrieval.
Advertisement

Certara stock holds steady after recent earnings update

https://www.ad-hoc-news.de/boerse/news/nebenwerte/certara-stock-holds-steady-after-recent-earnings-update/70136004
Certara stock is trading near recent levels on Nasdaq following its latest quarterly earnings release, which showed mixed revenue and profit trends. The company, a life-sciences software specialist, reported steady but not explosive revenue growth and healthy EBITDA margins, though net income was below prior-year peaks due to increased investments. Investors are evaluating its valuation and growth profile against sector peers, with analyst consensus generally constructive but tempered by more conservative growth assumptions.

Certara Launches External Data Accelerator for CDISC Standards Compliance

https://www.clinicaltrialvanguard.com/news/certara-launches-external-data-accelerator-for-cdisc-standards-compliance/
Certara has launched its External Data Accelerator to address the challenges of managing external clinical study data and ensuring compliance with CDISC standards. This solution integrates senior external data specialists with Pinnacle 21 Data Exchange to validate vendor data against FDA-used standards *before* it enters the study database, significantly reducing the cost and time associated with late-stage data remediation. The accelerator aims to prevent standards problems from surfacing at submission by enforcing conformance at the study setup phase.

This Certara Insider Increased Their Holding In The Last Year

https://www.moomoo.com/news/post/76348604/this-certara-insider-increased-their-holding-in-the-last-year
The article indicates that an insider at Certara has increased their holdings in the company over the past year. This action by an insider often suggests a belief in the company's future prospects. Further details would be needed to understand the significance of this increase.

New RSU award sets 2027–2028 vesting for Certara (CERT) interim CFO

https://www.stocktitan.net/sec-filings/CERT/form-4-certara-inc-insider-trading-activity-5c49313adb17.html
Certara, Inc. (CERT) has granted its Interim CFO, Mohammed Faiz, 63,532 Restricted Stock Units (RSUs) under the Certara 2020 Incentive Plan. These RSUs will vest in two equal installments on July 15, 2027, and July 15, 2028, contingent on his continued service. Each RSU represents a contingent right to one share of common stock or its cash equivalent, with the grant formalized on September 1, 2026.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

https://www.easternprogress.com/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-certara-inc-/article_b644c4f1-7d62-5809-a426-c9a8a280eae8.html
Pomerantz LLP is investigating Certara, Inc. (NASDAQ: CERT) for potential securities fraud and unlawful business practices. This investigation follows Certara's first-quarter 2026 financial results, which showed a decline in services revenue and bookings, and prompted a 19% drop in the company's stock price. Investors are encouraged to contact Pomerantz LLP to learn more about joining the class action.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement